Stryker has acquired Porex Surgical division from Porex Corporation, a portfolio company of Los Angeles-based investment firm Aurora Capital Group.
Porex Surgical makes products for craniofacial, neurosurgical, oculoplastic and aesthetic surgery.
Porex president and CEO William Midgette said that the transaction allows them to focus on their core customers and technologies, and enhance their industry leadership.
“We support the largest and most companies in the healthcare, bioscience, industrial and consumer sectors with the advanced porous plastic materials science technologies,” Midgette said.
“We are also pleased to have found a strategic partner for Surgical that is committed to the business’ success and will allow its own technology to reach its full potential.”
Stryker chairman, president and CEO Stephen MacMillan said that the acquisition of Porex Surgical further expands their presence in the Craniomaxillofacial (CMF) market and allows to broaden their product offering to both patients and clinicians.
Porex is a developer and manufacturer of porous plastic products. It primarily serves the healthcare and bioscience end markets.
Porex products serve filtration, venting, wicking and diffusing functions in applications such as blood filters, catheter vents, specialty filters, writing instrument tips and consumable diagnostic tests.